However, in a dose-escalation phase I trial, it was observed that treatment with avelumab (the only IgG1 mAb; other anti-PD-(L)1 mAbs are all IgG4) did not impact the frequencies of circulating PD-L1+CD4+ and CD8+ T cells in 12 different cancer types. Here, CD8A is linked to cancer.